iBio (NASDAQ:IBIO – Get Free Report) and Generate Biomedicines (NASDAQ:GENB – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for iBio and Generate Biomedicines, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iBio | 1 | 0 | 4 | 2 | 3.00 |
| Generate Biomedicines | 1 | 1 | 6 | 0 | 2.62 |
iBio presently has a consensus target price of $6.00, suggesting a potential upside of 631.71%. Generate Biomedicines has a consensus target price of $26.20, suggesting a potential upside of 174.63%. Given iBio’s stronger consensus rating and higher probable upside, equities research analysts clearly believe iBio is more favorable than Generate Biomedicines.
Insider and Institutional Ownership
7.9% of iBio shares are owned by institutional investors. 1.5% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares iBio and Generate Biomedicines”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iBio | $100,000.00 | 577.77 | -$33.04 million | ($0.28) | -2.93 |
| Generate Biomedicines | $31.89 million | 38.62 | -$203.15 million | ($2.27) | -4.20 |
iBio has higher earnings, but lower revenue than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares iBio and Generate Biomedicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iBio | N/A | -40.05% | -35.35% |
| Generate Biomedicines | -1,289.97% | -151.21% | -54.73% |
Summary
iBio beats Generate Biomedicines on 11 of the 13 factors compared between the two stocks.
About iBio
iBio, Inc. is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology. The company’s current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development. iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery.
About Generate Biomedicines
Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma.
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
